002019 亿帆医药
已收盘 07-10 15:00:00
资讯
新帖
简况
亿帆医药收盘上涨2.28%,滚动市盈率44.44倍,总市值174.67亿元
金融界 · 08:26
亿帆医药收盘上涨2.28%,滚动市盈率44.44倍,总市值174.67亿元
亿帆医药:合成生物技术产品预计四季度量产
证券之星 · 07-09 01:01
亿帆医药:合成生物技术产品预计四季度量产
亿帆医药:截止6月30日股东人数为41,120人
证券之星 · 07-09 01:01
亿帆医药:截止6月30日股东人数为41,120人
异动快报:亿帆医药(002019)7月8日9点49分触及涨停板
证券之星 · 07-08 01:50
异动快报:亿帆医药(002019)7月8日9点49分触及涨停板
亿帆医药:已计提的无形资产减值不允许转回
证券之星 · 07-04
亿帆医药:已计提的无形资产减值不允许转回
亿帆医药涨5.77%,太平洋二个月前给出“买入”评级,目标价15.00元
证券之星 · 07-01
亿帆医药涨5.77%,太平洋二个月前给出“买入”评级,目标价15.00元
亿帆医药:亿立舒在美国市场终端定价为4600美元/支
证券之星 · 06-26
亿帆医药:亿立舒在美国市场终端定价为4600美元/支
亿帆医药:全资子公司获得甘精胰岛素注射液临床试验批准通知书
格隆汇 · 06-25
亿帆医药:全资子公司获得甘精胰岛素注射液临床试验批准通知书
亿帆医药最新公告:全资子公司获得甘精胰岛素注射液临床试验批准通知书
证券之星 · 06-25
亿帆医药最新公告:全资子公司获得甘精胰岛素注射液临床试验批准通知书
研报掘金丨首创证券:维持亿帆医药“增持”评级,Ryzneuta成功实现向美国市场发货
格隆汇 · 06-23
研报掘金丨首创证券:维持亿帆医药“增持”评级,Ryzneuta成功实现向美国市场发货
每周股票复盘:亿帆医药(002019)股东户数增至3.95万户
证券之星 · 06-13
每周股票复盘:亿帆医药(002019)股东户数增至3.95万户
亿帆医药(002019)5月30日股东户数3.89万户,较上期减少4.21%
证券之星 · 06-05
亿帆医药(002019)5月30日股东户数3.89万户,较上期减少4.21%
亿帆医药:公司在售产品主要包括小儿青翘颗粒和复方银花解毒颗粒
证券之星 · 06-05
亿帆医药:公司在售产品主要包括小儿青翘颗粒和复方银花解毒颗粒
亿帆医药:2024年全球G-CSF药物市场规模维持在60亿美元左右
证券之星 · 06-05
亿帆医药:2024年全球G-CSF药物市场规模维持在60亿美元左右
亿帆医药:B6投产后有信心面对市场竞争
证券之星 · 06-05
亿帆医药:B6投产后有信心面对市场竞争
【机构调研记录】交银施罗德基金调研亿帆医药、福田汽车
证券之星 · 06-04
【机构调研记录】交银施罗德基金调研亿帆医药、福田汽车
【私募调研记录】金控资产调研亿帆医药
证券之星 · 06-04
【私募调研记录】金控资产调研亿帆医药
华大基因股价已超券商目标价,亿帆医药获“买入”评级丨券商评级观察
21世纪经济报道 · 05-30
华大基因股价已超券商目标价,亿帆医药获“买入”评级丨券商评级观察
亿帆医药涨9.41%,太平洋四周前给出“买入”评级,目标价15.00元
证券之星 · 05-29
亿帆医药涨9.41%,太平洋四周前给出“买入”评级,目标价15.00元
亿帆医药:截止2025年5月20日公司股东人数为40,658人
证券之星 · 05-26
亿帆医药:截止2025年5月20日公司股东人数为40,658人
加载更多
公司概况
公司名称:
亿帆医药股份有限公司
所属行业:
医药制造业
上市日期:
2004-07-13
主营业务:
亿帆医药股份有限公司的主营业务是医药产品、原料药和高分子材料的研发、生产、销售及药品推广服务。公司的主要产品是医药产品、维生素。截至2024年12月31日,公司累计获得专利、软件著作权和外观设计334个、商标604个(含著名商标5个、境外商标239个),其中PCT专利64个、马德里国际商标72个。
发行价格:
12.57
{"stockData":{"symbol":"002019","market":"SZ","secType":"STK","nameCN":"亿帆医药","latestPrice":14.36,"timestamp":1752131028000,"preClose":14.04,"halted":0,"volume":25545000,"delay":0,"changeRate":0.0228,"floatShares":841000000,"shares":1216000000,"eps":0.3232,"marketStatus":"已收盘","change":0.32,"latestTime":"07-10 15:00:00","open":14.09,"high":14.46,"low":13.97,"amount":365000000,"amplitude":0.0349,"askPrice":14.37,"askSize":82,"bidPrice":14.36,"bidSize":191,"shortable":0,"etf":0,"ttmEps":0.3232,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1752197400000},"marketStatusCode":5,"adr":0,"adjPreClose":14.04,"symbolType":"stock","openAndCloseTimeList":[[1752111000000,1752118200000],[1752123600000,1752130800000]],"highLimit":15.44,"lowLimit":12.64,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1216390085,"isCdr":false,"pbRate":1.96,"roa":"--","peRate":44.430693,"roe":"1.78%","epsLYR":0.32,"committee":-0.237872,"marketValue":17467000000,"turnoverRate":0.0304,"status":0,"floatMarketCap":12084000000},"requestUrl":"/m/hq/s/002019","defaultTab":"news","newsList":[{"id":"2550146886","title":"亿帆医药收盘上涨2.28%,滚动市盈率44.44倍,总市值174.67亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550146886","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550146886?lang=zh_cn&edition=full","pubTime":"2025-07-10 16:26","pubTimestamp":1752135997,"startTime":"0","endTime":"0","summary":"7月10日,亿帆医药今日收盘14.36元,上涨2.28%,滚动市盈率PE达到44.44倍,创19天以来新低,总市值174.67亿元。从行业市盈率排名来看,公司所处的化学制药行业市盈率平均55.26倍,行业中值32.91倍,亿帆医药排名第102位。截至2025年一季报,共有9家机构持仓亿帆医药,其中基金5家、其他4家,合计持股数6690.93万股,持股市值7.78亿元。亿帆医药股份有限公司的主营业务是医药产品、原料药和高分子材料的研发、生产、销售及药品推广服务。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/07/10162651605247.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0070","BK0185","BK0197","BK0077","BK0239","BK0191","002019"],"gpt_icon":0},{"id":"2550722935","title":"亿帆医药:合成生物技术产品预计四季度量产","url":"https://stock-news.laohu8.com/highlight/detail?id=2550722935","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550722935?lang=zh_cn&edition=full","pubTime":"2025-07-09 09:01","pubTimestamp":1752022882,"startTime":"0","endTime":"0","summary":"证券之星消息,亿帆医药(002019)07月08日在投资者关系平台上答复投资者关心的问题。投资者提问:请问,合成生物技术产品2'-岩藻糖基乳糖获得FDA GRAS安全认证后,准备什么时间开始量产?谢谢!亿帆医药回复:感谢您的关注和提问。预计在今年四季度左右可以量产。谢谢!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070900006070.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0070","002019","BK0185","BK0197","BK0191","BK0239"],"gpt_icon":0},{"id":"2550572235","title":"亿帆医药:截止6月30日股东人数为41,120人","url":"https://stock-news.laohu8.com/highlight/detail?id=2550572235","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550572235?lang=zh_cn&edition=full","pubTime":"2025-07-09 09:01","pubTimestamp":1752022882,"startTime":"0","endTime":"0","summary":"证券之星消息,亿帆医药(002019)07月08日在投资者关系平台上答复投资者关心的问题。投资者提问:请问截止6月30日,公司最新股东人数是多少?亿帆医药回复:您好,截止2025年6月30日公司股东人数为41,120人。谢谢!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070900006072.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0185","BK0239","BK0077","002019","BK0191","BK0070"],"gpt_icon":0},{"id":"2549567058","title":"异动快报:亿帆医药(002019)7月8日9点49分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2549567058","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549567058?lang=zh_cn&edition=full","pubTime":"2025-07-08 09:50","pubTimestamp":1751939442,"startTime":"0","endTime":"0","summary":"证券之星7月8日盘中消息,9点49分亿帆医药触及涨停板。目前价格15.11,上涨9.97%。其所属行业化学制药目前上涨。领涨股为富士莱。该股为创新药,合成生物,化学原料药概念热股,当日创新药概念上涨1.79%,合成生物概念上涨1.72%,化学原料药概念上涨1.71%。7月7日的资金流向数据方面,主力资金净流入1236.67万元,占总成交额5.74%,游资资金净流出1629.29万元,占总成交额7.56%,散户资金净流入392.62万元,占总成交额1.82%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070800009402.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0070","BK0191","BK0185","002019","BK0197","BK0077"],"gpt_icon":0},{"id":"2548339129","title":"亿帆医药:已计提的无形资产减值不允许转回","url":"https://stock-news.laohu8.com/highlight/detail?id=2548339129","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548339129?lang=zh_cn&edition=full","pubTime":"2025-07-04 08:48","pubTimestamp":1751590092,"startTime":"0","endTime":"0","summary":"证券之星消息,亿帆医药(002019)07月03日在投资者关系平台上答复投资者关心的问题。投资者提问:2023年,公司对F627无形资产计提8.48亿减值准备。而亿立舒2024年和今年销售很好,公司是否考虑在今年年报中重估F627的价值?亿帆医药回复:感谢您的关注和提问。根据现行会计准则,已计提的无形资产减值不允许转回;但公司会持续努力进一步深挖该产品的市场价值。谢谢!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070400006280.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0197","BK0239","BK0191","002019","BK0185","BK0070"],"gpt_icon":0},{"id":"2548079646","title":"亿帆医药涨5.77%,太平洋二个月前给出“买入”评级,目标价15.00元","url":"https://stock-news.laohu8.com/highlight/detail?id=2548079646","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548079646?lang=zh_cn&edition=full","pubTime":"2025-07-01 16:27","pubTimestamp":1751358435,"startTime":"0","endTime":"0","summary":"今日亿帆医药涨5.77%,收盘报13.74元。2025年4月30日,太平洋研究员周豫发布了对亿帆医药的研报《Q1业绩基本符合市场预期,创新药产品收入实现高速增长》,该研报对亿帆医药给出“买入”评级,认为其目标价为15.0元,现价距离目标价尚有9.17%的涨幅空间。维持“买入”评级。此外,天风证券研究员杨松,曹文清,华安证券研究员谭国超,任婉莹近期也对该股发布了研报,同样给出“买入”评级。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070100026780.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002019","601099"],"gpt_icon":0},{"id":"2546998202","title":"亿帆医药:亿立舒在美国市场终端定价为4600美元/支","url":"https://stock-news.laohu8.com/highlight/detail?id=2546998202","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546998202?lang=zh_cn&edition=full","pubTime":"2025-06-26 16:39","pubTimestamp":1750927154,"startTime":"0","endTime":"0","summary":"证券之星消息,亿帆医药(002019)06月26日在投资者关系平台上答复投资者关心的问题。投资者提问:据说f627在美国市场上的售价是每支4572美元,这是否属实?亿帆医药回复:感谢您的关注与提问。不属实,亿立舒在美国市场终端定价为4600美元/支。谢谢!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025062600025945.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0191","BK0077","BK0070","BK0185","002019","BK0197"],"gpt_icon":0},{"id":"2546211820","title":"亿帆医药:全资子公司获得甘精胰岛素注射液临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2546211820","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546211820?lang=zh_cn&edition=full","pubTime":"2025-06-25 18:41","pubTimestamp":1750848077,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1583","002019","BK0197","BK0239","BK1141","BK0191","0O59.UK","BK0077","BK1576","BK0185","03347","BK0070","BK5011"],"gpt_icon":0},{"id":"2546115262","title":"亿帆医药最新公告:全资子公司获得甘精胰岛素注射液临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2546115262","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546115262?lang=zh_cn&edition=full","pubTime":"2025-06-25 18:40","pubTimestamp":1750848048,"startTime":"0","endTime":"0","summary":"亿帆医药(002019.SZ)公告称,公司全资子公司亿帆医药(上海)有限公司于2025年6月24日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》,同意开展甘精胰岛素注射液的生物类似药临床试验。该产品为生物类似药,原研产品为赛诺菲公司的来得时®,本次申请的适应症与来得时®目前在中国获批的适应症一致,为需用胰岛素治疗的成人1型和2型糖尿病,青少年和年龄在6岁及以上儿童的1型糖尿病。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025062500031766.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0191","BK0239","BK0197","BK1141","BK0185","BK0077","03347","BK0070","BK1583","BK1576","002019"],"gpt_icon":0},{"id":"2545493230","title":"研报掘金丨首创证券:维持亿帆医药“增持”评级,Ryzneuta成功实现向美国市场发货","url":"https://stock-news.laohu8.com/highlight/detail?id=2545493230","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2545493230?lang=zh_cn&edition=full","pubTime":"2025-06-23 16:06","pubTimestamp":1750666003,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0191","002019","BK0239","0P6S.UK","BK0070","601136","BK5011","BK0185","BK0197","BK0276","BK0077","BK4139","PBM"],"gpt_icon":0},{"id":"2543763224","title":"每周股票复盘:亿帆医药(002019)股东户数增至3.95万户","url":"https://stock-news.laohu8.com/highlight/detail?id=2543763224","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2543763224?lang=zh_cn&edition=full","pubTime":"2025-06-14 03:33","pubTimestamp":1749843208,"startTime":"0","endTime":"0","summary":"截至2025年6月13日收盘,亿帆医药报收于14.64元,较上周的13.14元上涨11.42%。本周,亿帆医药6月13日盘中最高价报15.21元,股价触及近一年最高点。本周关注点股本股东变化:截至2025年6月10日公司股东户数为3.95万户,较5月30日增加596.0户,增幅为1.53%股本股东变化近日亿帆医药披露,截至2025年6月10日公司股东户数为3.95万户,较5月30日增加596.0户,增幅为1.53%。户均持股数量由上期的3.12万股减少至3.08万股,户均持股市值为41.22万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025061400008047.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0191","BK0239","BK0197","BK0185","BK0070","BK0077","002019"],"gpt_icon":0},{"id":"2541023330","title":"亿帆医药(002019)5月30日股东户数3.89万户,较上期减少4.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2541023330","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2541023330?lang=zh_cn&edition=full","pubTime":"2025-06-05 17:17","pubTimestamp":1749115022,"startTime":"0","endTime":"0","summary":"证券之星消息,近日亿帆医药披露,截至2025年5月30日公司股东户数为3.89万户,较5月20日减少1713.0户,减幅为4.21%。在化学制药行业个股中,亿帆医药股东户数高于行业平均水平,截至5月30日,化学制药行业平均股东户数为3.23万户。从股价来看,2025年5月20日至2025年5月30日,亿帆医药区间涨幅为4.06%,在此期间股东户数减少1713.0户,减幅为4.21%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025060500024544.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0239","BK0191","002019","BK0070","BK0185","BK0077"],"gpt_icon":0},{"id":"2541012604","title":"亿帆医药:公司在售产品主要包括小儿青翘颗粒和复方银花解毒颗粒","url":"https://stock-news.laohu8.com/highlight/detail?id=2541012604","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2541012604?lang=zh_cn&edition=full","pubTime":"2025-06-05 11:37","pubTimestamp":1749094645,"startTime":"0","endTime":"0","summary":"证券之星消息,亿帆医药(002019)06月04日在投资者关系平台上答复投资者关心的问题。投资者提问:公司有没有治疗风热的药啊,因为马上要变天气了,最多不出半个月,广东昨天那一场雨带有湿气,很多人感冒发烧,后面要天气要往风热转变了,请问公司有这些知识储备吗?亿帆医药回复:感谢您的关注与提问。公司在售产品主要包括小儿青翘颗粒和复方银花解毒颗粒。谢谢!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025060500011726.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0185","BK0077","002019","BK0191","BK0197","BK0239"],"gpt_icon":0},{"id":"2541012520","title":"亿帆医药:2024年全球G-CSF药物市场规模维持在60亿美元左右","url":"https://stock-news.laohu8.com/highlight/detail?id=2541012520","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2541012520?lang=zh_cn&edition=full","pubTime":"2025-06-05 11:37","pubTimestamp":1749094635,"startTime":"0","endTime":"0","summary":"证券之星消息,亿帆医药(002019)06月04日在投资者关系平台上答复投资者关心的问题。投资者提问:雪球上有文章称“2025年全球注射升白细胞药物市场规模达到180亿美元”,这数据准确吗?如果不准确,请公司详细介绍一下2025年全球注射升白细胞药物市场情况,及亿立舒市场预期占比。亿帆医药回复:感谢您的关注与提问。根据Frost&Sullivan统计,2024年全球G-CSF药物市场规模维持在60亿美元左右;随着亿立舒在更多市场上市,其占比将逐渐提高。谢谢!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025060500011715.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0239","BK0070","BK0077","002019","BK0191","BK0185"],"gpt_icon":0},{"id":"2541801293","title":"亿帆医药:B6投产后有信心面对市场竞争","url":"https://stock-news.laohu8.com/highlight/detail?id=2541801293","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2541801293?lang=zh_cn&edition=full","pubTime":"2025-06-05 11:37","pubTimestamp":1749094626,"startTime":"0","endTime":"0","summary":"证券之星消息,亿帆医药(002019)06月04日在投资者关系平台上答复投资者关心的问题。投资者提问:据报下半年公司的B6新产能将正式投产。请问:根据该产品目前的市场竞争态势和公司的生产经营成本等情况,公司的B6投产后能够快速实现盈利吗?谢谢!亿帆医药回复:感谢您的关注与提问。B6投产后有信心面对市场竞争。谢谢!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025060500011708.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0191","002019","BK0185","BK0070","BK0239","BK0077","BK0197"],"gpt_icon":0},{"id":"2540208327","title":"【机构调研记录】交银施罗德基金调研亿帆医药、福田汽车","url":"https://stock-news.laohu8.com/highlight/detail?id=2540208327","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2540208327?lang=zh_cn&edition=full","pubTime":"2025-06-04 08:03","pubTimestamp":1748995404,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及6月3日披露的机构调研信息,交银施罗德基金近期对2家上市公司进行了调研,相关名单如下:1)亿帆医药 调研纪要:亿帆医药的核心产品亿立舒2024年纳入医保,中国境内终端净销售超5亿元,预计2025年销量进一步提升。2)福田汽车 调研纪要:福田汽车2025年核心业务集中在重卡、新能源和国际化。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025060400004151.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0188","BK0239","BK0012","BK0017","BK0070","BK0264","BK0028","600166","BK0185","BK0197","BK0191","002019"],"gpt_icon":0},{"id":"2540083447","title":"【私募调研记录】金控资产调研亿帆医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2540083447","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2540083447?lang=zh_cn&edition=full","pubTime":"2025-06-04 08:02","pubTimestamp":1748995368,"startTime":"0","endTime":"0","summary":"根据市场公开信息及6月3日披露的机构调研信息,知名私募金控资产近期对1家上市公司进行了调研,相关名单如下:1)亿帆医药 调研纪要:亿帆医药的核心产品亿立舒2024年纳入医保,中国境内终端净销售超5亿元,预计2025年销量进一步提升。美国市场2025年5月底发货,合作伙伴crotech公司上调市场预期,已签发2025年采购订单超4万支。公司对研发创新更加理性与谨慎,F-652治疗酒精性肝炎研究由美国合作科研机构开展。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/RB2025060400004138.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0191","002019","BK0239","BK0070","BK0185","BK0197","BK0077"],"gpt_icon":0},{"id":"2539213837","title":"华大基因股价已超券商目标价,亿帆医药获“买入”评级丨券商评级观察","url":"https://stock-news.laohu8.com/highlight/detail?id=2539213837","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2539213837?lang=zh_cn&edition=full","pubTime":"2025-05-30 09:25","pubTimestamp":1748568300,"startTime":"0","endTime":"0","summary":"值得注意的是,华大基因虽然获得增持评级,但华泰金融控股(香港)给予的最高目标价却低于其收盘价。评级调高方面,5月29日,券商调高上市公司评级达到1家次,中银国际证券对联化科技的评级从“增持”调高至“买入”。首次覆盖方面,5月29日券商共给出了2次首次覆盖,其中亿帆医药获得国投证券给予“买入”评级,扬杰科技获得华源证券给予“增持”评级。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2025-05-30/doc-ineyiarh8850339.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-05-30/doc-ineyiarh8850339.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["300676","002019"],"gpt_icon":0},{"id":"2539906232","title":"亿帆医药涨9.41%,太平洋四周前给出“买入”评级,目标价15.00元","url":"https://stock-news.laohu8.com/highlight/detail?id=2539906232","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2539906232?lang=zh_cn&edition=full","pubTime":"2025-05-29 16:30","pubTimestamp":1748507451,"startTime":"0","endTime":"0","summary":"今日亿帆医药涨9.41%,收盘报13.25元。2025年4月30日,太平洋研究员周豫发布了对亿帆医药的研报《Q1业绩基本符合市场预期,创新药产品收入实现高速增长》,该研报对亿帆医药给出“买入”评级,认为其目标价为15.0元,现价距离目标价尚有13.21%的涨幅空间。维持“买入”评级。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为太平洋的周豫。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052900024391.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601099","002019"],"gpt_icon":0},{"id":"2538123031","title":"亿帆医药:截止2025年5月20日公司股东人数为40,658人","url":"https://stock-news.laohu8.com/highlight/detail?id=2538123031","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2538123031?lang=zh_cn&edition=full","pubTime":"2025-05-26 11:33","pubTimestamp":1748230400,"startTime":"0","endTime":"0","summary":"证券之星消息,亿帆医药(002019)05月26日在投资者关系平台上答复投资者关心的问题。投资者提问:尊敬的董秘 你好 衷心感谢你们不厌其烦回答投资者的提问。请问贵公司2025年5月20日A股股东人数是多少?谢谢亿帆医药回复:您好,截止2025年5月20日公司股东人数为40,658人。谢谢!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052600010228.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0191","BK0070","BK0077","BK0197","BK0185","002019","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1752152647870,"stockEarnings":[{"period":"1week","weight":0.0233},{"period":"1month","weight":0.04},{"period":"3month","weight":0.3012},{"period":"6month","weight":0.3879},{"period":"1year","weight":0.1852},{"period":"ytd","weight":0.3205}],"compareEarnings":[{"period":"1week","weight":0.0111},{"period":"1month","weight":0.0274},{"period":"3month","weight":0.0836},{"period":"6month","weight":0.1024},{"period":"1year","weight":0.1803},{"period":"ytd","weight":0.0422}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"亿帆医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"41120人(较上一季度增加0.08%)","perCapita":"20463股","listingDate":"2004-07-13","address":"浙江省杭州市临安区临安经济开发区","registeredCapital":"121639万元","survey":" 亿帆医药股份有限公司的主营业务是医药产品、原料药和高分子材料的研发、生产、销售及药品推广服务。公司的主要产品是医药产品、维生素。截至2024年12月31日,公司累计获得专利、软件著作权和外观设计334个、商标604个(含著名商标5个、境外商标239个),其中PCT专利64个、马德里国际商标72个。","listedPrice":12.57},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"亿帆医药(002019)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供亿帆医药(002019)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"亿帆医药,002019,亿帆医药股票,亿帆医药股票老虎,亿帆医药股票老虎国际,亿帆医药行情,亿帆医药股票行情,亿帆医药股价,亿帆医药股市,亿帆医药股票价格,亿帆医药股票交易,亿帆医药股票购买,亿帆医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"亿帆医药(002019)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供亿帆医药(002019)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}